Additionally, a main strength point in the present study is the assessment of both local and systemic chemerin levels allowing for better elucidation of the systemic effects of the therapeutic use of Omega-3FAs in conjunction with nonsurgical periodontal therapy in patients with periodontitis and type II diabetes mellitus. This evidence concerns the gene RARRES2 and type 2 diabetes mellitus.